Royal Bank of Canada Cuts Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Royal Bank of Canada trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 268,857 shares of the medical equipment provider's stock after selling 28,276 shares during the period. Royal Bank of Canada owned 0.39% of Lantheus worth $24,052,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. ProShare Advisors LLC raised its position in Lantheus by 41.2% during the fourth quarter. ProShare Advisors LLC now owns 22,646 shares of the medical equipment provider's stock valued at $2,026,000 after purchasing an additional 6,606 shares during the period. MPM Bioimpact LLC increased its stake in Lantheus by 57.3% in the fourth quarter. MPM Bioimpact LLC now owns 236,213 shares of the medical equipment provider's stock worth $21,132,000 after purchasing an additional 86,031 shares during the period. Man Group plc increased its stake in Lantheus by 87.0% in the fourth quarter. Man Group plc now owns 199,304 shares of the medical equipment provider's stock worth $17,830,000 after purchasing an additional 92,701 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Lantheus by 4.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,212 shares of the medical equipment provider's stock worth $3,508,000 after purchasing an additional 1,531 shares during the last quarter. Finally, LRI Investments LLC boosted its position in Lantheus by 8.4% in the 4th quarter. LRI Investments LLC now owns 3,107 shares of the medical equipment provider's stock valued at $278,000 after buying an additional 240 shares during the period. 99.06% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,109 shares of company stock valued at $6,016,046. 2.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have commented on LNTH. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Truist Financial dropped their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Lantheus presently has an average rating of "Buy" and an average target price of $132.67.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded up $0.01 during trading on Friday, reaching $75.53. The stock had a trading volume of 180,885 shares, compared to its average volume of 987,339. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89. The business has a fifty day moving average price of $92.56 and a 200-day moving average price of $91.72. The stock has a market cap of $5.23 billion, a PE ratio of 12.59 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the previous year, the business posted $1.69 earnings per share. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. Sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.